Article Text

Download PDFPDF

897-G SR-8541A, a small molecule inhibitor of ENPP1, enhances the effect of immune checkpoint inhibitors in a colorectal cancer model
  1. Alexis Weston1,2,
  2. Trason Thode1,2,
  3. Serina Ng1,
  4. Tithi Ghosh-Halder1,
  5. Katelyn Gutowsky1,
  6. Brian Durbin1,
  7. Raffaella Soldi1,
  8. Monil Shah2,
  9. Jonathan Northrup2,
  10. Srinivas Kasibhatla1,2,
  11. Mohan Kaadige1,2 and
  12. Sunil Sharma2
  1. 1Translational Genomics Research Institute, Phoenix, AZ
  2. 2Stingray Therapeutics, Houston, TX
  • Journal for ImmunoTherapy of Cancer (JITC) preprint. The copyright holder for this preprint are the authors/funders, who have granted JITC permission to display the preprint. All rights reserved. No reuse allowed without permission.


Background The five-year survival rate for colorectal cancer (CRC) remains at 14% despite improvements in early detection and development of novel treatments, including immune checkpoint inhibitors (ICIs). The immune landscape of CRC is heterogeneous and complex, posing challenges in treatment decision-making.1 2 Colorectal tumors presenting with microsatellite stable (MSS) or mismatch repair proficiency (MMRP) account for 85% of CRCs, which show little immune activity and respond poorly to ICIs. New therapeutic strategies to overcome ICI resistance are needed to achieve a durable anti-tumor response in MSS/MMRP CRC.3 4 About 85% of CRCs exhibit chromosomal instability, which results in chromosome segregation errors and micronuclei formation. The latter releases dsDNA into the cytosol, stimulating a cyclic GMP-AMP synthase (cGAS)-Stimulator of Interferon Genes (STING)-dependent innate immune response. Preclinical studies have shown that activation of STING in the tumor microenvironment leads to induction of an interferon (IFN) response, activation of dendritic cells, and stimulation of T-cell responses. It is anticipated that activation of the innate immune response may help increase sensitivity to ICIs.5 6 The therapeutic benefit from direct STING agonists is limited due to the widespread expression of STING in normal tissues. Ectonucleotide Pyrophosphatase/Phosphodiesterase-1 (ENPP1) is the only known direct negative regulator of the STING pathway that hydrolyzes 2’3’ cGAMP, the direct activator of STING. Highest levels of 2′3′ cGAMP can be found in tumors and recent evidence suggests that 2′3′ cGAMP acts locally, as a paracrine immune transmitter.7 8 Therefore, inhibition of ENPP1 may produce superior outcomes by activating STING in the tumor microenvironment. We have developed SR-8541A, a highly selective and potent inhibitor of ENPP1. Additionally, we show that the inhibition of ENPP1 with SR-8541A enhances the effect of ICIs in colorectal cancer models.

Methods In vivo studies were conducted using colorectal syngeneic mouse model (CT-26), which was engrafted subcutaneously and treated with SR-8541A ± α-CTLA4 ± α-PD-1 antibodies. Tumor growth and body weight were monitored over the course of the studies. IHC, RT-PCR, and mass spec analysis to identify adenosine levels were conducted on the tumors.

Results In vivo combination of SR-8541A with ICIs exhibited a significant increase in overall efficacy compared to ICIs alone. Tumors treated with the combination showed increased levels of CD3+ and CD8+ T-cell infiltration, increased levels of IFN response, and decreased levels of adenosine.

Conclusions Use of ENPP1 inhibition may sensitize colorectal cancers to immune checkpoint inhibition. We intend to explore this combination in the clinic.


  1. Bai J, Chen H, Bai X. Relationship between microsatellite status and immune microenvironment of colorectal cancer and its application to diagnosis and treatment. J Clin Lab Anal 2021;35:e23810. PubMed PMID: 33938589; PMCID: PMC8183910.

  2. Kreidieh M, Mukherji D, Temraz S, Shamseddine A. Expanding the scope of immunotherapy in colorectal cancer: current clinical approaches and future directions. Biomed Res Int 2020;2020:9037217. PubMed PMID: 32090113; PMCID: PMC7008242.

  3. San-Roman-Gil, et al. Current landscape and potential challenges of immune checkpoint inhibitors in microsatellite stable metastatic colorectal carcinoma. Cancers (Basel) 2023;15. PubMed PMID: 36765821; PMCID: PMC9913409.

  4. Kunac, et al. Activation of cGAS-STING pathway is associated with MSI-H stage IV colorectal cancer. Cancers (Basel) 2022;15. PubMed PMID: 36612217; PMCID: PMC9818394.

  5. Beernaert B, Parkes EE. cGAS-STING signalling in cancer: striking a balance with chromosomal instability. Biochem Soc Trans 2023;51:539–555. PubMed PMID: 36876871.

  6. Chon J, et al. STING signaling is a potential immunotherapeutic target in colorectal cancer. J Cancer 2019;10:4932–4938. PubMed PMID: 31598165; PMCID: PMC6775531.

  7. Schadt, et al. Cancer-Cell-Intrinsic cGAS expression mediates tumor immunogenicity. Cell Rep 2019;29:1236–1248 e7. PubMed PMID: 31665636.

  8. Kaneta A, et al. Role of the cGAS-STING pathway in regulating the tumor-immune microenvironment in dMMR/MSI colorectal cancer. Cancer Immunol Immunother 2022;71:2765–2776. PubMed PMID:

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.